Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adjuvant atezolizumab plus platinum doublet in resected EGFR-mutated stage II–IIIA NSCLC
jRCT2080224772Phase 2Completed
- Sponsor
- Nobuyuki Yamamoto (Coordinating Investigator)
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC) and EGFR-mutated non-small cell lung cancer, sponsored by Nobuyuki Yamamoto (Coordinating Investigator). Started Jul 2019; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080224772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224772.